XML 52 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Assets:      
Fair value of assets   $ 358,901 $ 427,084
Liabilities:      
Contingent consideration payable   21,247 19,700
Deferred compensation plan liability   3,874 2,732
Fair value of liabilities   25,121 22,432
Exchange agreement, aggregate principal amount   247,200  
Milestone payment, stock issued as consideration   9,000  
Common Stock      
Liabilities:      
Milestone payment, stock issued as consideration $ 9,300    
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc      
Liabilities:      
Contingent consideration payable   $ 20,999  
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Minimum | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.75  
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Maximum | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.78  
Commercial paper      
Assets:      
Fair value of assets   $ 112,026 115,141
Asset-backed securities      
Assets:      
Fair value of assets   73,093 68,135
Corporate debt securities      
Assets:      
Fair value of assets   169,558 240,726
Money market funds      
Assets:      
Fair value of assets   4,224 3,082
Level 2      
Assets:      
Fair value of assets   358,901 427,084
Liabilities:      
Contingent consideration payable   0 0
Deferred compensation plan liability   3,874 2,732
Fair value of liabilities   3,874 2,732
Convertible debt, fair value   6,100  
Level 2 | Commercial paper      
Assets:      
Fair value of assets   112,026 115,141
Level 2 | Asset-backed securities      
Assets:      
Fair value of assets   73,093 68,135
Level 2 | Corporate debt securities      
Assets:      
Fair value of assets   169,558 240,726
Level 2 | Money market funds      
Assets:      
Fair value of assets   4,224 3,082
Level 3      
Liabilities:      
Contingent consideration payable   21,247 19,700
Deferred compensation plan liability   0 0
Fair value of liabilities   $ 21,247 $ 19,700
Level 3 | ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc      
Liabilities:      
Discount rate   0.101